Dobetyle T Tablet contains Calcium Dobesilate 500 mg and Troxerutin 500 mg, a specialized combination formulated to support vascular health and improve microcirculatory function. The medicine is used in conditions associated with impaired blood vessel function, venous insufficiency, and microvascular disorders. By helping maintain capillary integrity and promoting healthy circulation, the formulation contributes to improved vascular performance and patient comfort under medical supervision.
Calcium Dobesilate helps reduce capillary permeability and fragility while improving blood flow through the microcirculation. It supports vascular stability and helps minimize fluid leakage from small blood vessels. Troxerutin, a bioflavonoid derivative, possesses vasoprotective and antioxidant properties that help strengthen blood vessel walls, improve venous tone, and support healthy circulation. Together, these ingredients provide comprehensive support for vascular and capillary health.
The tablet is commonly prescribed for chronic venous insufficiency, varicose vein-related symptoms, hemorrhoids, diabetic microangiopathy, and other conditions involving compromised microcirculation as advised by a healthcare professional. Regular use may help reduce symptoms such as swelling, heaviness in the legs, discomfort, and vascular-related complications while supporting overall circulatory health.
With the increasing prevalence of vascular disorders, diabetes-related complications, and venous circulation problems, Dobetyle T Tablet maintains strong demand in the cardiovascular and vascular care segment. Its clinically relevant combination, physician acceptance, and growing need for microcirculation management solutions contribute to sustained market potential. The product offers valuable business opportunities and long-term growth prospects for retailers and distributors operating within the specialty cardiovascular pharmaceutical sector.